openPR Logo
Press release

Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyvero™ LRT Trial

05-15-2014 06:26 PM CET | Health & Medicine

Press release from: Curetis AG

/ PR Agency: akampion
Mayo Clinic’s Dr. Robin Patel Named Principal Investigator

− Curetis adds six new trial sites, significantly expanding U.S. clinical trial network for ongoing FDA study

Holzgerlingen, Germany, May 14, 2014 -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that Robin Patel, M.D., Professor of Medicine and Microbiology at the Mayo Clinic in Rochester, Minn., has been named Lead Principal Investigator of the company’s Unyvero™ LRT Application FDA trial. The lower respiratory tract (LRT) application is designed to detect 17 pathogens and 22 antibiotic resistance gene markers of clinical importance in patients with suspected LRT infections. The Company also announced the addition of six new clinical trial sites in the last few quarters, expanding its clinical trial network to nine high-profile testing sites.

Dr. Patel, who chairs the Division of Clinical Microbiology and Mayo Clinic’s Bacteriology Laboratory and directs the Infectious Diseases Research Laboratory, is a specialist in the clinical detection and identification of bacteria, including the characterization of their antimicrobial resistance and susceptibility, particularly for biofilm-mediated infections. She succeeds Prof. Christine Ginocchio, M.D., formerly of North Shore-LIJ Health System Laboratories, who recently left North Shore-LIJ to assume a corporate position in the microbiology field.

“We are thrilled that Dr. Patel, a renowned physician heading one of the largest microbiology departments in the U.S. – and already an important part of this trial as Principal Investigator at Mayo Clinic for the last six months – has agreed to take on an expanded role as Lead Principal Investigator,” said Anne Thews, M.D., Medical Director of Curetis AG. “Robin is adept at relating her leading antimicrobial resistance and susceptibility expertise across indications, from respiratory tract to prosthetic joint infections. Because of this fluency in the resistance space, we believe this appointment will set the stage for Robin’s support of additional U.S. trials using Curetis’ Unyvero solution.”

“I also wish to thank Dr. Christine Ginocchio, who has been instrumental in the design and launch of our Unyvero LRT trial,” Dr. Thews added.

“I am honored to follow Dr. Ginocchio as Lead Principal Investigator of this trial investigating the performance of a highly multiplexed panel targeting multiple bacteria and antibiotic resistance genes in lower respiratory tract samples,” said Dr. Patel. “This is a new approach in diagnosing severe infections and it addresses an unmet medical need.”

To bolster enrollment and to capture potential geographical differences in pathogen and antibiotic resistance gene distribution, Curetis has also expanded its clinical trial network from three to nine testing sites over the past couple of quarters.

“We are proud to have attracted prominent, highly experienced and committed trial centers,” said Oliver Schacht, Ph.D., CEO of Curetis AG. “With these new sites now active, we are confident that we can complete enrollment by the end of the year, positioning Curetis to submit an application for FDA approval of the Unyvero™ LRT application in 2015.”

Participating trial centers testing at least 2,000 prospective lower respiratory tract samples include:

• David Geffen School of Medicine at UCLA (Los Angeles, Calif.)
• Johns Hopkins University School of Medicine (Baltimore, Md.)
• Northwestern Memorial Hospital (Chicago, Ill.)
• Mayo Clinic (Rochester, Minn.)
• North Shore-LIJ Health System Laboratories (Lake Success, N.Y.)
• University of Rochester Medical Center (Rochester, N.Y.)
• Weis Research Center/Geisinger Health System (Danville, Penn.)
• University of Washington Medical Center (Seattle, Wash.)
• William Beaumont Hospital (Royal Oak, Mich.)

Disclaimer
CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero™ technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero™ product which may be sold at some future point in time in the U.S. have not yet been established.

###

About the Unyvero™ System
The CE-marked Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result. It is marketed in Europe, Russia, the Middle East and various other non-European countries. In the U.S., Curetis is running a prospective multi-center clinical trial aimed at achieving FDA clearance registered under http://www.clinicaltrials.gov/ NCT01922024.
The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.
Thereby, clinically relevant information is available within about four hours to support an informed therapy decision as early as possible.
The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. The second CE-marked application, the Unyvero™ i60 ITI cartridge for implant & tissue infections, is also commercially available in Europe. Cartridges for additional indications are in various stages of development and preparation.

About Curetis AG
Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised total funds of over €49.1 million (~ USD 65 million). The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical, Sanofi Pasteur and Cempra Inc. as well as several international distribution agreements covering more than 20 countries.

Contact
Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
p(at)curetis.com
www.curetis.com

International Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

U.S. Media Inquiries
The Ruth Group
Melanie Sollid-Penton
msollid(at)theruthgroup.com
Tel. +1 646 536 7023

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyvero™ LRT Trial here

News-ID: 287805 • Views: 4795

More Releases from Curetis AG

Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
- Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples - Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more
Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of Unyve …
- German family firm ‘Scholz-HTIK – High Tech in Kunststoff’ has been selected by Curetis based on systematic benchmarking process - Holzgerlingen (Germany), December 4, 2012 -- Curetis AG today announced a strategic supply chain partnership with German family business Horst Scholz GmbH + Co. KG for the production of high-quality plastics parts for its Unyvero™ Cartridge. Under the agreement, Curetis will invest more than € 2 million in multi-cavity tools for
Curetis Completes Enrollment for its EU Trial As Planned
- Prospective multi-center trial enrolls 800 patient samples in 7 months - Holzgerlingen (Germany), October 9, 2012 -- Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero™ Pneumonia Application on schedule. More than 800 patient samples were collected until September 30, 2012. Data analysis will be completed in early 2013. Subsequently, results will be published in a major, peer-reviewed journal. The trial will compare the
Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia
- Partners to start registration process and market launch in Russia - Holzgerlingen, Germany, September 27, 2012 -- Curetis AG today announced that it has signed up BioLine LLC as an exclusive distribution partner for Russia, Ukraine, Kazakhstan and Belorus. BioLine is a major player in these markets and distributor for global companies such as Becton Dickinson, Leica Microsystems and many others. BioLine is preparing the registration of the Unyvero™ Solution and

All 5 Releases


More Releases for Unyvero

Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
- Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples - Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more
Curetis Completes Enrollment for its EU Trial As Planned
- Prospective multi-center trial enrolls 800 patient samples in 7 months - Holzgerlingen (Germany), October 9, 2012 -- Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero™ Pneumonia Application on schedule. More than 800 patient samples were collected until September 30, 2012. Data analysis will be completed in early 2013. Subsequently, results will be published in a major, peer-reviewed journal. The trial will compare the
Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia
- Partners to start registration process and market launch in Russia - Holzgerlingen, Germany, September 27, 2012 -- Curetis AG today announced that it has signed up BioLine LLC as an exclusive distribution partner for Russia, Ukraine, Kazakhstan and Belorus. BioLine is a major player in these markets and distributor for global companies such as Becton Dickinson, Leica Microsystems and many others. BioLine is preparing the registration of the Unyvero™ Solution and
Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherland …
- Partners prepare market launch and clinical evaluation project - Holzgerlingen, Germany, September 26, 2012 -- Curetis AG today announced that Curetis and Mediphos have closed an exclusive distribution agreement for the Netherlands. Mediphos is an experienced independent distributor with a clear focus on molecular diagnostics and an emphasis on microbiology-based applications. Under the agreement, both companies will prepare the market roll-out of Curetis´ Unyvero™ Solution and the Unyvero™ P50 Pneumonia
Curetis and Heraeus Medical Collaborate on the Development of New Unyvero™ Dia …
- Joint development of cartridge for orthopaedics, wound and surgery infections - Holzgerlingen and Wehrheim (Germany), September 20, 2012 -- Curetis AG and Heraeus Medical GmbH have signed a collaboration agreement to jointly develop a novel Unyvero™ cartridge for the detection of pathogens and antibiotic resistances in implant & tissue infections (ITI). One key application area will be in orthopaedics, e.g. to diagnose infections after knee and hip replacement surgeries. Under
Curetis AG Achieves CE-Marking for Unyvero™ Solution and Initiates Commerciali …
- Successful completion of performance evaluation study; CE Mark for Unyvero™ instrument system and pneumonia application - Holzgerlingen, Germany, May 14, 2012 -- Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced that the company has achieved the CE marking for its Unyvero™ suite of instruments and the P50 Pneumonia Cartridge and that is has already initiated national